ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Eligible participants, who participated in the ADAGIO trial and who sign an approved informed
consent form, will be enrolled into the study at their original study locations. participants
who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical
benefit from restarting treatment can also be considered for enrollment in the Core follow-up
study period. Use of any other anti-PD treatment is permitted as deemed necessary by the
treating physician (according to the participants clinical status).
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries